media


 

 

Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome

Results affirm the advantages of Prota’s remission peanut OIT treatments, which lead to significant and sustained benefits including substantially improved Health Related Quality of Life

Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024

Prota Therapeutics’ CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards

Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate

First Company to Validate Significant Quality of Life Improvements Compared with Standard Care

Prota Therapeutics Achieves Peanut Allergy Treatment Milestone:

Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients

Prota Press Release - Appointment of Patrick Machado

Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado

Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial.

Media release (prota) New data shows previously allergic children still able to tolerate peanut four years after treatment with a novel immunotherapy licensed by Prota Therapeutics

Melbourne, Australia: Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota) is pleased to announce results from a follow up study of the probiotic and peanut immunotherapy (PPOIT) treatment which it has licensed from the Murdoch Childrens Research Institute (MCRI), demonstrating long-lasting tolerance effects of treatment more than four years after the original study ended.

Researchers discover two treatments that induce peanut allergy remission in children

The research, led by the Murdoch Children’s Research Institute (MCRI), found the treatments – a combination of a probiotic together with oral immunotherapy (the gradual introduction of the allergenic food) and oral
immunotherapy alone – significantly induced remission and desensitisation.